RVNC Revance Therapeutics Inc

Revance Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications.

$14.61  -0.19 (-1.28%)
As of 12/03/2021 15:59:57 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/06/2014
Outstanding shares:  71,794,852
Average volume:  1,063,702
Market cap:   $1,062,563,810
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    761330109
ISIN:        US7613301099
Sedol:      BJFSR99
Valuation   (See tab for details)
PE ratio:   -3.54
PB ratio:   8.73
PS ratio:   16.87
Return on equity:   -246.77%
Net income %:   -470.81%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy